Quibim, a global leader in medical imaging analysis, consolidated its growth in the United States by closing 2022 with a 5x revenue growth due to its collaborations with radiologists, hospitals, and top-tier pharmaceutical companies. The company’s goal is to accurately predict patient outcomes using data extracted from medical images to avoid unnecessary patient procedures.
Many doctors do not perform repeated biopsies or track tumor resistance over time as a standard-of-care procedure. In addition, molecular biology techniques have limited accessibility, high cost, and long turnaround times, causing time-to-treatment delays of approximately 2-3 weeks in time-sensitive diseases such as lung cancer. As a perfect companion, medical imaging exams, such as MRIs, CT scans, and PET scans, are performed at every single step of the disease. Quibim’s innovative business model takes advantage of these standard-of-care scans offering different software solutions that deeply analyze the image and extract critical information to detect and diagnose diseases earlier.
Also Read: Decodable Achieves GDPR Compliance, Receiving Industry Validation of Enterprise-Level Security
The company’s Artificial Intelligence (AI)-based medical devices, QP-Prostate®, marketed in the United States and Europe, and QP-Brain®, sold in Europe, intend to reduce the workload of healthcare professionals by independently performing detailed analysis and comparison of medical images, thereby automatically and accurately pre-populating radiological reports. As images are Quibim’s primary data source, the company participates yearly in international congresses in the medical imaging field. Quibim presented its medical imaging solutions and vision of transforming imaging data into actionable predictions at the Radiological Society of North America (RSNA) Congress.
SOURCE: PR Newswire